Abstract
Monoclonal antibodies (mAbs) are the treatment of choice for high-risk ambulatory persons with mild to moderate COVID-19. We studied viral culture dynamics post-treatment in a subset of participants receiving the mAb bamlanivimab in the ACTIV-2 trial. Viral load by qPCR and viral culture were performed from anterior nasal swabs collected on study days 0 (day of treatment), 1, 2, 3, and 7. Treatment with mAb resulted in rapid clearance of culturable virus in participants without treatment-emergent resistance. One day after treatment, 0 of 28 (0%) participants receiving mAb and 16 of 39 (41%) receiving placebo still had culturable virus (p <0.0001); nasal viral loads were only modestly lower in the mAb-treated group at days 2 and 3. Recrudescence of culturable virus was detected in three participants with emerging mAb resistance and viral load rebound. The rapid reduction in shedding of viable SARS-CoV-2 after mAb treatment highlights the potential role of mAbs in preventing disease transmission.
Competing Interest Statement
JB, MC, RD, JR, JPF, CRC, MDH, JR, CM, JAD, ACJ, RWC, JSC, and AKB report no competing interests. KWC reports research grant support to the institution from Merk Sharp & Dohme. AN and PK are employees and shareholders of Eli Lilly. ALG declares central testing contracts with Abbott, and research support from Gilead and Merck, outside of the submitted work. WF reports research funding from Ridgeback Biopharmaceuticals, consultancy fees from Roche and Merck, and serves on adjudication committees for Janssen and Syneos. ESD reports consulting fees from Gilead Sciences and Merck and research support to the institution from Gilead Sciences and ViiV. JJE reports serving as an ad hoc consultant to GSK/VIR and as data monitoring committee (DMC) chair for Adagio Phase III studies. DMS reports consulting fees from the following companies: Fluxergy, Kiadis, Linear Therapies, Matrix BioMed, Arena Pharmaceuticals, VxBiosciences, Model Medicines, Bayer Pharmaceuticals, Signant Health and Brio Clinical. JZL reports consulting for Abbvie and Recovery Therapeutics.
Clinical Trial
The clinical trial registration for the parent study A5401/ACTIV-2 is NCT04518410
Clinical Protocols
Funding Statement
This work was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number 3UM1AI068636-14S2, UM1 AI068634, UM1 AI068636 and UM1 AI106701. The viral culture work was performed in the Ragon Institute BSL3 core, which is supported in part by the NIH-funded Harvard University Center for AIDS Research (P30 AI060354). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The viral culture work was performed in the Ragon Institute BSL3 core, which is supported in part by the NIH-funded Harvard University Center for AIDS Research (P30 AI060354).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Study protocol approval and ethical oversight was performed by a central Institutional Review Board (Advarra, Inc.).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Co-communicating
Data Availability
The authors confirm that all data underlying the findings are fully available. Due to ethical restrictions, study data are available upon request from sdac.data@sdac.harvard.edu with the written agreement of the AIDS Clinical Trials Group and the manufacturer of the investigational product.
